Methods for treating a posterior segment of an eye
AssigneeAllergan, Inc.
InventorsRobert T. Lyons, James N. Chang, John T. Trogden, Scott M. Whitcup
Life of this patent
Estimating the term…
Abstract
Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.
Claims18
A method of treating an ocular posterior segment disorder comprising administering a composition to a posterior segment of an eye of a human or animal, the composition comprising:
- (a) about 2% to about 8% triamcinolone;
- (b) about 2.3% to about 2.5% sodium hyaluronate;
- (c) about 0.6% to about 0.63% sodium chloride
- (d) about 0.3% dibasic sodium phosphate;
- (e) about 0.04% monobasic sodium phosphate;
- (f) water, and
- (g) no added preservative,
- wherein the composition has a viscosity of about 200,000 cps at a shear rate of 0.1/second and provides a triamcinolone half life of at least 19 days after administration.
A method of treating an ocular posterior segment disorder, the method comprising the step of administering a composition to a posterior segment of an eye of a human or animal, the composition comprising:
- (a) about 2% to about 8% triamcinolone, the triamcinolone being present in a plurality of particles that remain substantially uniformly suspended in the composition for at least 1 year without requiring resuspension processing, (b) about 2.3% to about 2.5% sodium hyaluronate;
- (c) about 0.6% to about 0.63% sodium chloride;
- (d) about 0.3% dibasic sodium phosphate;
- (e) about 0.04% monobasic sodium phosphate;
- (f) water, and (g) no added preservative, wherein the composition has a viscosity of about 200,000 cps at a shear rate of 0.1/second and provides a triamcinolone half life of at least 19 days.
A method of treating an ocular posterior segment disorder comprising administering a composition to a posterior segment of an eye of a human or animal, the composition consisting essentially of:
- (a) about 8% triamcinolone;
- (b) about 2.3% sodium hyaluronate;
- (c) about 0.6% sodium chloride
- (d) about 0.3% dibasic sodium phosphate;
- (e) about 0.04% monobasic sodium phosphate;
- (f) water, and
- (g) no added preservative,
- wherein the composition has a viscosity of about 200,000 cps at a shear rate of 0.1/second and provides a triamcinolone half life of at least 19 days after administration.
A method of treating an ocular posterior segment disorder comprising administering a composition to a posterior segment of an eye of a human or animal, the composition consisting of:
- (a) 2% to 8% triamcinolone;
- (b) about 2.3% to about 2.5% sodium hyaluronate;
- (c) no added preservative;
- and
- (d) opthalmically acceptable excipients comprising about 0.6% to about 0.63% sodium chloride, about 0.3% dibasic sodium phosphate, about 0.04% monobasic sodium phosphate, and water;
- wherein the composition has a viscosity of about 200,000 cps at a shear rate of 0.1/second and provides a triamcinolone half life of at least 19 days after administration.
Dependencies are inferred from the claim text.